<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 51-year-old woman developed very severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> complicated by <z:hpo ids='HP_0003774'>chronic renal failure</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>She underwent ATG therapy, resulting in a transient effect </plain></SENT>
<SENT sid="2" pm="."><plain>Thereafter, <z:hpo ids='HP_0000083'>renal insufficiency</z:hpo> progressed, followed by the induction of CAPD therapy </plain></SENT>
<SENT sid="3" pm="."><plain>Although rabbit ATG (rATG) was administered as the next immunotherapy for <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> persisted and she experienced repeated episodes of severe <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> including MRSA and <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal infections</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>She was transplanted with peripheral blood stem cells from her HLA-haploidentical son after a reduced-intensity conditioning regimen that included <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (three days of 30 mg/kg), fludarabine (two days of 20 mg/m(2)) and rATG (three days of 2.5 mg/kg) </plain></SENT>
<SENT sid="5" pm="."><plain>FK506 (0.03 mg/kg/24H) was administered for the prophylaxis of GVHD </plain></SENT>
<SENT sid="6" pm="."><plain>Prompt trilineage engraftment occurred, resulting in the improvement of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Three months after grafting, she succumbed to cerebrovascular disease, although there was no apparent GVHD and she had remained well with stable hematopoiesis </plain></SENT>
</text></document>